Monotherapy versus Combination Therapy in Patients Hospitalized with Community-Acquired Pneumonia
Tóm tắt
Current international guidelines for the management of community acquired pneumonia (CAP) recommend therapy with a β-lactam plus a macrolide or a ‘respiratory’ fluoroquinolone alone in patients hospitalized in a medical ward, and combination therapy with a β-lactam plus a macrolide or a fluoroquinolone in patients hospitalized in the intensive care unit. However, which of the available options should be preferred remains a matter of debate, and there are surprisingly few prospective randomized trials strictly comparing mono-versus dual therapy strategies in CAP patients. Thus, the recommendation of combining a macrolide with a β-lactam rather than using a β-lactam alone in hospitalized patients is derived mainly from observational data, and the suggested combination of a β-lactam with a fluoroquinolone in severe CAP has been rarely examined in a clinical trial. As there have been sound theoretical arguments for and against combination therapy regimens, the rationale for the different options is discussed and available clinical trial data are reviewed in this article. A final conclusion about the superiority of one antibacterial regimen over another in hospitalized patients with CAP cannot be drawn on the basis of the limited data available. So far, combination therapy probably should be preferred in all patients presenting with severe pneumonia, whereas in general, combination therapy is not necessary in patients in a medical ward, and combination therapy with a β-lactam plus a macrolide or monotherapy with a respiratory fluoroquinolone should be considered equivalent in this latter patient group. On the other hand, the available data demonstrate that empirical coverage of atypical bacteria in all patients with mild-to-moderate CAP seems unnecessary, and β-lactam monotherapy might perform equally well when compared with respiratory fluoroquinolones in patients with non-severe CAP. Thus, the alternative use of a β-lactam alone at adequate dosage in clinically stable patients seems justified, if CAP due to Legionella pneumophila is unlikely.
Tài liệu tham khảo
American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Am J Respir Crit Care Med 2001; 163: 1730–54
British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults. Thorax 2001; 56 Suppl. IV: iv1–iv64
Macfarlane JT, Boldy D. 2004 update of BTS pneumonia guidelines: what’s new? Thorax 2004 May; 59(5): 364–6
Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347–82
Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003 Dec; 37: 1405–33
Mandell LA, Marrie TJ, Grossman RF, et al. Canadian Community-Acquired Pneumonia Working Group. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000; 31: 383–421
Höffken G, Lorenz J, Kern W, et al. Guidelines of the Paul-Ehrlich-Society for Chemotherapy, the German Respiratory Society, the German Society for Infectiology and the Competence Network CAPNETZ Germany for the epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults. Chemotherapie J 2005; 14(4): 97–155
Woodhead M, Blasi F, Ewig S, et al. ERS task force in collaboration with ESCMID: guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138–80
Schouten JA, Prins JM, Bonten M, et al. Revised SWAB guidelines for antimicrobial therapy of community-acquired pneumonia. Neth J Med 2005 Sep; 63(8): 323–35
El Solh AA, Sikka P, Ramadan F, et al. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med 2001; 163: 645–51
Jacobs MR, Felmingham D, Appelbaum PC, et al. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003 Aug; 52(2): 229–46
Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia caused by Gram-negative bacteria: incidence risk and prognosis. Arch Intern Med 2002; 162(16): 1849–58
Mera RM, Miller LA, Daniels JJ, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States over a 10-year period: Alexander Project. Diagn Microbiol Infect Dis 2005 Mar; 51(3): 195–200
Doern GV, Richter SS, Miller A, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis 2005 Jul; 41(2): 139–48
Fogarty C, Goldschmidt R, Bush K. Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis 2000; 31(2): 613–5
Kelley MA, Weber DJ, Gilligan P, et al. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000; 31(4): 1008–11
Waterer GW, Wunderink RG, Jones CB. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest 2000; 118(6): 1839–40
Kays MB, Wack MF, Smith DW, et al. Azithromycin treatment failure in community-acquired pneumonia caused by Streptococcus pneumoniae resistant to macrolides by a 23S rRNA mutation. Diagn Microbiol Infect Dis 2002; 43(2): 163–5
Musher DM, Dowell ME, Shortridge VD, et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002; 346(8): 630–1
Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35(5): 556–64
Van Kerkhoven D, Peetermans WE, Verbist L, et al. Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams. J Antimicrob Chemother 2003; 51(3): 691–6
Lynch JP, Martinez FJ. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin Infect Dis 2002; 34 Suppl. 1: S27–46
Jacobs MR. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure. Clin Infect Dis 2002 Sep; 35: 565–9
Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37(2): 230–7
Aspa J, Rajas O, Rodriguez de Castro F, et al. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis 2004 Mar; 38(6): 787–98
File Jr TM, Lode H, Kurz H, et al. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults. Antimicrob Agents Chemother 2004 Sep; 48(9): 3323–31
Musher DM, Bartlett JG, Doern GV. A fresh look at the definition of susceptibility of Streptococcus pneumoniae to β-lactam antibiotics. Arch Intern Med 2001; 161: 2538–44
Vanderkooi OG, Low DE, Green K, et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005 May; 40: 1288–97
Martinez FJ. Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients. Clin Infect Dis 2004 May; 38 Suppl. 4: S328–40
Norrby SR, Petermann W, Willcox PA, et al. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 1998; 30(4): 397–404
Kalbermatter V, Bagilet D, Diab M, et al. Oral levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization. Med Clin (Barc) 2000 Nov; 115(15): 561–3
Petitpretz P, Arvis P, Marel M, et al. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001; 119(1): 185–95
Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med 2004; 198: 708–20
Höffken G, Talan D, Larsen LS, et al. Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens. Eur J Clin Microbiol Infect Dis 2004 Oct; 23(10): 772–5
Gleason PP, Meehan TP, Fine JM, et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159(21): 2562–72
Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161(15): 1837–42
Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ 2005 Feb; 330(7489): 456–12
Shefet D, Robenshtok E, Paul M, et al. Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. Arch Intern Med 2005 Sep; 165(17): 1992–2000
Ewig S, Ruiz M, Mensa J, et al. Severe community-acquired pneumonia: assessment of severity criteria. Am J Respir Crit Care Med 1998; 158: 1102–8
Ball P, Baquero F, Cars O, et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 2002; 49: 31–40
Epstein BJ, Gums JG. Optimal pharmacological therapy for community-acquired pneumonia: the role of dual antibacterial therapy. Drugs 2005; 65(14): 1949–71
Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170(4): 440–4
Paterson DL. “Collateral damage” from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004; 38 Suppl. 4: S341–5
Veziris N, Truffot-Pernot C, Aubry A, et al. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 2003 Oct; 47(10): 3117–22
Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4(8): 519–27
Drago L, De Vecchi E, Nicola L, et al. In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin. J Antimicrob Chemother 2005 Aug; 56(2): 353–9
Lister PD, Wolter DJ. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa. Clin Infect Dis 2005 Feb; 40 Suppl. 2: 105–14
Paul M, Benuri-Silbiger I, Soares-Weiser K, et al. β-Lactam monotherapy versus β-lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004; 328(7441): 668
Bliziotis IA, Samonis G, Vardakas KZ, et al. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 2005 Jul; 41(2): 149–58
Tamaoki J. The effects of macrolides on inflammatory cells. Chest 2004; 125: 41S–50S
Schultz MJ. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother 2004; 54: 21–8
Yates B, Murphy DM, Forrest IA, et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2005; 172: 772–5
Khalid M, Al Saghir A, Saleemi S, et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J 2005 Mar; 25(3): 490–3
Frank E, Liu J, Kinasewitz G, et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther 2002; 24(8): 1292–308
Fogarty C, Siami G, Kohler R, et al. Multicenter, open-label, randomised study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults. Clin Infect Dis 2004; 38: S16–23
Zervos M, Mandell LA, Vrooman PS, et al. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. Treat Respir Med 2004; 3(5): 329–36
Portier H, Brambilla C, Garre M, et al. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors. Eur J Clin Microbiol Infect Dis 2005 Jun; 24(6): 367–76
Loh LC, Quah SY, Khoo SK, et al. Addition of macrolide in treating adult hospitalized community-acquired pneumonia. Respirology 2005 Jun; 10(3): 371–7
Lin E, Stanek RJ, Mufson MA. Lack of synergy of erythromycin combined with penicillin or cefotaxime against Streptococcus pneumoniae in vitro. Antimicrob Agents Chemother 2003; 47: 1151–3
Sun HK, Lee SY, Banevicius MA, et al. Efficacy of pulsatile amoxicillin and clarithromycin dosing alone and in combination in a murine pneumococcal pneumonia model. J Antimicrob Chemother 2005 Sep; 56(3): 559–65
Johansen HK, Jensen TG, Dessau RB, et al. Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo. J Antimicrob Chemother 2000; 46: 973–80
Jenkins SG, Lewis JW. Synergistic interaction between ofloxacin and cefotaxime against common clinical pathogens. Infection 1995 May–Jun; 23(3): 154–61
Pohlman JK, Knapp CC, Ludwig MD, et al. Timed killing kinetic studies of the interaction between ciprofloxacin and beta-lactams against gram-negative bacilli. Diagn Microbiol Infect Dis 1996 Sep; 26(1): 29–33
Flatz L, Cottagnoud M, Kuhn F, et al. Ceftriaxone acts synergistically with levofloxacin in experimental meningitis and reduces levofloxacin-induced resistance in penicillin-resistant pneumococci. J Antimicrob Chemother 2004 Feb; 53(2): 305–10
Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978–1997. Am J Med 1999; 107(1A): 34S–43S
Burgess DS, Lewis JS. Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. Clin Ther 2000 Jul; 22(7): 872–8
Houck PM, MacLehose RF, Niederman MS, et al. Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997. Chest 2001; 119(5): 1420–6
Brown RB, Iannini P, Gross P, et al. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest 2003; 123(5): 1503–11
Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003 Feb; 36: 389–95
Weiss K, Low DE, Cortes L, et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J 2004 Nov–Dec; 11(8): 589–93
Garcia Vazquez E, Mensa J, Martinez JA, et al. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. Eur J Clin Microbiol Dis 2005; 24: 190–5
Mortensen EM, Restrepo MI, Anzueto A, et al. The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia. Crit Care 2006; 10: R8
Oosterheert JJ, Bonten MJM, Hak E, et al. How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review. J Antimicrob Chemother 2003; 52(4): 555–63
Waterer GW. Combination antibiotic therapy with macrolides in community-acquired pneumonia: more smoke but is there any fire? Chest 2003 May; 123(5): 1328–9
Dudas V, Hopefl A, Jacobs R, et al. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother 2000; 34: 446–52
Querol-Ribelles JM, Tenias JM, Querol-Borras JM, et al. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization. Int J Antimicrob Agents 2005 Jan; 25(1): 75–83
Aspa J, Rajas O, Rodriguez de Castro F, et al. Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 2006; 27: 1010–9
Menendez R, Torres A, Zalacain R, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004 Nov; 59(11): 960–5
Leroy O, Saux P, Bedos JP, et al. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 2005 Jul; 128(1): 172–83
Finch R, Schürmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002 Jun; 46: 1746–54
Welte T, Petermann W, Schurmann D, et al. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis 2005 Dec; 41(12): 1697–705
Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003 Sep; 37: 752–60
Vergis EN, Indorf A, File TM, et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients. Arch Intern Med 2000 May; 160: 1294–300
Plouffe J, Schwartz DB, Kolokathis A, et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. Antimicrob Agents Chemother 2000 Jul; 44(7): 1796–802
Paladino JA, Sperry HE, Backes JM, et al. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med 1991 Nov; 91(5): 462–70
Dresser LD, Niederman MS, Paladino JA. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest 2001 May; 119(5): 1439–48
Hedlund J, Ortqvist A. Management of patients with community-acquired pneumonia treated in hospital in Sweden. Scand J Infect Dis 2002; 34: 887–92
Höffken G, Niederman MS. The importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 2002; 122(6): 2183–96